Strontium guidance unchanged

NICE has again reissued its advice on the use of strontium ranelate (Protelos).

There is no change to the agency’s 2008 recommendation that the drug should be prescribed on the NHS for primary and secondary prevention of osteoporotic fractures only in patients at high risk of osteoporotic fractures who are unable to tolerate oral bisphosphonates.

NICE was obliged to re-examine its original judgment in 2010 after failing to disclose the underlying economic assumptions. The latest reassessment marks final confirmation of the guidance.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases